COMPANY

Braveheart Bio

HQ: San Francisco, CA source · braveheart.bio ↗

Keywords: cardiovascular cardiovascular disease Hypertrophic Obstructive Cardiomyopathy BHB-1893

Location: San Francisco, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Sep 2, 2026 Trial start Phase 3: BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy source ↗

2028-10 (ESTIMATED) · Phase 3 · BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy · NCT07755904

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07755904	BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy	Phase 3	Recruiting	Sep 2, 2026	2028-10 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗